BioXcel Therapeutics, Inc.
BTAIBioXcel Therapeutics is a biopharmaceutical company that utilizes a proprietary artificial intelligence platform and machine learning algorithms to develop transformative medicines in neuroscience and immuno-oncology.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
Profile
BioXcel Therapeutics is a biopharmaceutical company that utilizes a proprietary artificial intelligence platform and machine learning algorithms to develop transformative medicines in neuroscience and immuno-oncology. The company's core value proposition involves leveraging existing approved drugs or clinically evaluated candidates to identify new therapeutic indications, aiming to reduce development costs and accelerate timelines for diseases with high unmet medical needs.
A pioneer in AI-driven drug repurposing with an FDA-approved product in the acute agitation market.
Questions, answered.
- What is BioXcel Therapeutics, Inc.'s market cap?
- BioXcel Therapeutics, Inc. (BTAI) has a market capitalization of $26.8M and trades on NASDAQ.
- Who are BioXcel Therapeutics, Inc.'s competitors?
- BioXcel Therapeutics, Inc.'s key competitors include Acadia Pharmaceuticals, Xenon Pharmaceuticals Inc, Neurocrine Biosciences Inc, and others. These companies compete in similar markets and product categories.
- What subsidiaries does BioXcel Therapeutics, Inc. have?
- BioXcel Therapeutics, Inc.'s subsidiaries include OnkosXcel Therapeutics.
- Where is BioXcel Therapeutics, Inc. headquartered?
- BioXcel Therapeutics, Inc. is headquartered in United States of America and employs approximately 74 people. It has been publicly traded since 2018.